Abstract
Antibody formation is an intended physiological reaction to a “non-self” protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.
Keywords: Immunogenicity, biotechnology derived proteins, benefit/risk, risk assessment, regulatory guideline
Current Drug Safety
Title: Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals
Volume: 5 Issue: 4
Author(s): Isabel C. Buttel, Katrin Voller and Christian K. Schneider
Affiliation:
Keywords: Immunogenicity, biotechnology derived proteins, benefit/risk, risk assessment, regulatory guideline
Abstract: Antibody formation is an intended physiological reaction to a “non-self” protein intentionally triggered in the case of vaccines. However, an unwanted immune response to a therapeutic protein may lead to a loss of efficacy and/or to severe side effects. The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) issued a multidisciplinary guideline providing general recommendations from a marketing authorisation perspective on how to systematically assess an unwanted immune response following the administration of a biological drug. In this article, we discuss key aspects of this guideline and its concept, with a particular focus on the impact of immunogenicity on benefit/risk estimation of a therapeutic protein.
Export Options
About this article
Cite this article as:
Buttel C. Isabel, Voller Katrin and Schneider K. Christian, Immunogenicity and its Impact on Benefit/Risk Considerations in the Authorisation of Biopharmaceuticals, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792245993
DOI https://dx.doi.org/10.2174/157488610792245993 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Turning Points in the Life Course: Current Findings and Future Directions in Drug Use Research
Current Drug Abuse Reviews Melanocortin Receptors, Melanotropic Peptides and Penile Erection
Current Topics in Medicinal Chemistry Reaction Phenotyping in Drug Discovery: Moving Forward with Confidence?
Current Drug Metabolism Glycine Reuptake Inhibition as a New Therapeutic Approach in Schizophrenia: Focus on the Glycine Transporter 1 (GlyT1)
Current Pharmaceutical Design Epigenetics and Sjogren’s Syndrome
Current Pharmaceutical Biotechnology Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems
Current Vascular Pharmacology Increased Expression of the Remodeling- and Tumorigenic-Associated Factor Osteopontin in Pyramidal Neurons of the Alzheimers Disease Brain
Current Alzheimer Research Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics The Interleukin-1 System: An Attractive and Viable Therapeutic Target in Neurodegenerative Disease
Current Drug Targets - CNS & Neurological Disorders Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry The Era of Cerebellar Therapy
Current Neuropharmacology Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Current Medicinal Chemistry Granulocyte Colony-stimulating Factor as the Expecting Sword for the Treatment of Severe Sepsis
Current Pharmaceutical Design Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets Kidney Dysfunction is Associated with a High Burden of Cerebral Small Vessel Disease in Primary Intracerebral Hemorrhage
Current Neurovascular Research Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Progress in the Development of Selective TRPV1 Antagonists for Pain
Current Topics in Medicinal Chemistry Cancer Vaccines in Phase II/III Clinical Trials: State of the Art and Future Perspectives
Current Cancer Drug Targets Efficacy of Contingency Management for Cocaine Dependence Treatment: A Review of the Evidence
Current Drug Abuse Reviews